MedTrace Logo

RCVR (Residual CardioVascular Risk) Prospective Study

NCT06619353 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-02-18

No results posted yet for this study

Summary

The goal of this observational study is to evaluate whether residual cardiovascular risk assessed at 1 month after percutaneous coronary intervention (PCI) is associated with long-term clinical outcomes in adult patients with coronary artery disease who are free from major adverse clinical events at 1 month after PCI. The main questions it aims to answer are:

* Does residual cardiovascular risk at 1 month after PCI predict long-term net adverse clinical events?
* Which components of residual cardiovascular risk are associated with subsequent adverse clinical outcomes?

Participants will:

* Undergo comprehensive laboratory testing at 1 month after PCI and annually thereafter.
* Undergo artificial intelligence-based quantitative coronary angiographic analysis using DICOM datasets after PCI.
* Be followed annually for up to 3 years after the 1-month assessment to evaluate clinical outcomes.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood Sample

Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.

OTHER

DICOM Dataset

Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.

Sponsors & Collaborators

  • CHA University

    lead OTHER

Principal Investigators

  • Seung-Yul Lee, MD · CHA Bundang Medical Center

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2029-02-28
Completion
2029-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619353 on ClinicalTrials.gov